HEIH: The Potential Drug Target and Biomarker (G100859930)

Target Name: HEIH

NCBI ID: G100859930

HEIH

HEIH: The Potential Drug Target and Biomarker

HeLa cells, or HeLa cells, are a type of cancer cell that has been widely used in the study of human cancer. These cells are derived from the primary brain tumor of the African green monkey, and have been found to be highly resistant to chemotherapy and radiation therapy. They are often used as a testing ground for new cancer treatments.

One of the challenges in the study of cancer is identifying potential drug targets. A drug target is a molecule that is thought to contribute to the growth and survival of cancer cells. Identifying these targets is important for the development of new cancer treatments.

HEIH is a potential drug target that has been identified in the study of HeLa cells. This molecule is thought to contribute to the growth and survival of HeLa cells, and could be a useful target for new cancer treatments.

HEIH is a protein that is found in the cell membrane of HeLa cells. It is made up of two subunits, called HEIHA and HEIHB. These subunits are held together by a disulfide bond, and are located at the ends of the cell membrane.

HEIHA and HEIHB are both involved in the regulation of cell signaling processes. They are thought to play a role in the signaling pathways that are responsible for the growth and survival of HeLa cells.

One of the promising aspects of HEIH as a drug target is its relatively simple structure. This makes it easier to identify and target the molecule. Additionally, because it is a protein, it is less likely to cause unintended side effects that could be harmful to the body.

Another potential advantage of HEIH as a drug target is its role in the development of cancer. HeLa cells are often used as a testing ground for new cancer treatments, and because of their high resistance to chemotherapy and radiation therapy, they can be difficult to treat. Identifying a drug target, such as HEIH, could be the key to developing new treatments for these difficult-to-treat cells.

In conclusion, HEIH is a potential drug target and biomarker that has been identified in the study of HeLa cells. Its simple structure and role in the development of cancer make it an attractive target for new treatments. Further research is needed to fully understand the potential of this molecule as a drug.

Protein Name: Hepatocellular Carcinoma Up-regulated EZH2-associated Long Non-coding RNA

The "HEIH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HEIH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets